Many COVID-19 patients have pre-existing cardiovascular diseases, which are strongly linked to the high incidence of severe COVID-19. The experts advised such patients to prioritize drug treatments as per the physician’s recommendations to avoid aggravation of the basic diseases. Hence, the development of an analytical approach for the concurrent determination of drugs prescribed for the co-treatment of COVID-19 and cardiovascular diseases acquires significant importance in QC units and bioavailability centers. Herein, a micellar-UPLC approach was first devised for the concomitant analysis of aspirin, atenolol, atorvastatin, losartan, favipiravir, and remdesivir as co-administered drugs, either with or without salicylic acid. On ACQUITY UPLC C18 column, the aforesaid drugs were isocratically separated employing a micellar eluent system. This system consisted of 0.03 M Brij-35, 0.15 M sodium dodecyl sulfate, and 0.02 M sodium dihydrogen phosphate (pH 5.0) as the mobile phase A (90%) and n-propanol as the mobile phase B (10%). The eluent system was pumped at a flow rate of 0.50 mL.min− 1 for 5.50 min, which was suddenly increased to 0.80 mL.min− 1 for 2.50 min. The separated peaks were scanned at 240 nm. The suggested approach was validated following ICH requirements for linearity, robustness, accuracy, specificity, precision, and detection and quantitation limits. The suggested approach was applied successfully to commercial products and human plasma without any intrusion from excipients or plasma matrices. The suggested approach’s greenness was appraised employing five metrics namely: eco-scale, GAPI, NEMI, Raynie and Driver, and AGREE. Furthermore, the suggested approach’s whiteness features were investigated using the recently unveiled RGB12 model. The suggested approach outperformed the reported approaches in terms of greenness and whiteness. The sensitivity, high sample throughput, and short runtime (7.40 min) of the suggested approach assert its aptness for routine determination of the aforesaid drug